An equity cure is a clause in a leveraged loan agreement that lets a borrower’s owners, usually a private equity sponsor, contribute fresh cash to fix a broken financial covenant instead of triggering a default. The injection doesn’t change how the business actually performed. It changes the covenant math: the sponsor writes a check, the numbers are recalculated with that money added in, and the breach disappears on paper.
Why the Provision Exists
Leveraged loans typically include financial maintenance covenants that test the borrower’s health every quarter. The two common tests are the leverage ratio (total debt divided by EBITDA) and the interest coverage ratio (EBITDA divided by interest expense). A loan might require leverage to stay under 4.0x or coverage to stay above 1.25x. Miss either figure by any margin and the borrower is in technical default.
Technical default gives lenders the contractual right to declare an event of default and accelerate the loan, making the entire outstanding balance due immediately. That is a severe outcome for a company that may have had a single rough quarter. The equity cure is the safety valve. It gives the sponsor a narrow window to shore up the numbers with outside capital so lenders don’t reach for acceleration.
This matters most in deals built on maintenance covenants. Broadly syndicated “covenant-lite” loans, which only test compliance when the borrower voluntarily does something like issue new debt, rarely need cures because there is no periodic test to fail. Equity cures show up predominantly in middle-market and private credit transactions.
How the Cure Works
When quarterly financials reveal a breach, the cure clock starts. The sponsor typically has around 10 business days after financial statements are delivered to fund the contribution, though the window can stretch to 20 business days or more depending on the agreement. Miss that deadline and the cure right for that period is gone.
The money comes in as common equity, preferred equity, or deeply subordinated debt that lenders have agreed in advance to treat as equity for covenant purposes. The source is almost always the financial sponsor or parent company. Once the cash arrives, the agreement dictates how it gets applied.
The EBITDA Add-back Method
The most common approach treats the injected cash as an add-back to EBITDA for the breached testing period. If the maximum leverage ratio is 4.0x and the company came in at 4.2x, the sponsor contributes enough cash to lift the adjusted EBITDA figure and push the ratio back under the threshold. The denominator grows, the ratio shrinks, and the breach vanishes.
This adjustment exists only for covenant calculation. It does not change GAAP financial statements or actual operating results. The resulting number is sometimes called Pro Forma EBITDA or Adjusted EBITDA, and it only matters for the single question of whether the covenant was met.
Sponsors prefer this method because of the leverage effect. Debt is usually several multiples of EBITDA, so a small addition to EBITDA moves the ratio a lot. A company with $200 million in debt and $48 million in EBITDA (4.17x leverage) only needs about $2 million added to EBITDA to drop below a 4.0x covenant, compared with roughly $17 million in debt repayment to reach the same ratio.
The Debt Paydown Method
A less common alternative requires the sponsor’s cash to prepay loan principal, reducing the debt figure rather than boosting EBITDA. It’s more expensive because it takes far more capital to move the ratio the same distance. It also typically requires a permanent reduction in the lender’s commitment, so the borrower can’t re-borrow what it just paid down.
Many middle-market agreements combine both. The cure amount is first credited to EBITDA to clear the breach, then the borrower must use the same proceeds to prepay the loan. Lenders like this structure because it fixes the covenant problem and reduces credit exposure at the same time. The agreement will specify that the prepayment does not retroactively lower the debt figure for the breached measurement period, so the sponsor cannot double-count the benefit.
The Cure Window and Default Status
The period between breach and completed cure is legally uncomfortable. The default technically exists during that window, and the borrower is in breach of the credit agreement. The equity cure provision includes a built-in forbearance: lenders agree not to accelerate or charge default interest while the cure is pending, provided the sponsor meets the funding deadline.
That forbearance is narrow. It covers only the specific financial covenant breach being cured. If the borrower is simultaneously in default for another reason, like a missed interest payment or a violated non-financial covenant, the cure does nothing for it. And if the sponsor fails to fund on time, the forbearance evaporates and lenders regain full enforcement rights.
Frequency Caps and Amount Limits
Cures are not unlimited. The provision is meant to bridge a bad quarter, not to prop up a struggling business indefinitely. Agreements usually impose two frequency limits: a cap on consecutive use and a lifetime cap. A common structure allows no more than two cures in any four consecutive fiscal quarters, with three or four cures permitted over the life of the facility. These caps prevent papering over sustained decline with quarterly cash infusions.
Each injection is also sized tightly. The sponsor can only contribute the minimum needed to bring the breached ratio back into compliance. Some agreements further cap the cure at a percentage of EBITDA, with 15 percent a common ceiling. The point is to stop the provision from becoming a backdoor equity contribution for general corporate purposes.
What happens to the money afterward is also restricted. In agreements that don’t require immediate prepayment, the cash generally has to stay on the borrower’s balance sheet for working capital rather than being distributed out to shareholders. Lenders want the balance sheet genuinely strengthened, not just inflated for a single measurement date.
How Cured EBITDA Carries Forward
One of the most heavily negotiated points is what happens to the artificial EBITDA boost in later quarters. Financial covenants usually measure performance on a trailing four-quarter basis, so an unchecked add-back from Q1 would keep inflating results in Q2, Q3, and Q4 as those quarters roll through the same lookback window.
Lender-friendly agreements exclude the cured amount from all future covenant calculations. The add-back counts only for the single period of the breach. Once that quarter rolls off, compliance has to stand on actual operating results. Sponsors prefer to let the benefit linger, and the outcome depends on the relative bargaining power at the time the loan is negotiated.
What Using a Cure Signals
A completed cure eliminates the default for the affected period. The breach is treated as if it never happened, acceleration rights disappear, and the loan is back in good standing on paper.
In practice it’s a flare. The need for a cure tells lenders that performance has fallen below what everyone underwrote at closing, and lenders do not forget that. Future conversations about amendments, refinancing, or maturity extensions happen against the backdrop of a borrower that already missed a covenant. Lenders may push for tighter terms, higher pricing, or additional collateral.1SSRN. The Use of Equity Cures in Debt Contracts
What Happens Without a Cure
When the cure right has been exhausted or the sponsor declines to fund, the consequences move quickly. The uncured breach becomes a full event of default, giving lenders the right to accelerate. The damage rarely stops there.
Most leveraged borrowers carry debt across multiple instruments: a senior secured term loan, a revolver, and often second-lien notes or unsecured bonds. Nearly all of these agreements include cross-default provisions that trigger a default under one instrument when the borrower defaults under another. A single uncured covenant breach can therefore topple an entire capital structure in short order, pushing the company toward restructuring or bankruptcy. That is the underlying reason sponsors treat equity cures as critical. The cost of the injection is almost always less than the cost of a cascading cross-default.
Effect on Minority Shareholders
When the sponsor injects new equity to fund a cure, someone’s ownership percentage shrinks. If the cure takes the form of newly issued shares or a new class of preferred equity, minority investors who don’t participate face dilution. Their economic stake falls while the sponsor’s rises, and minority holders often have no say in whether the cure is exercised.
How much dilution actually results depends on how the cure is structured and how many times the sponsor uses the right. A single small injection may barely register. Multiple cures over the life of the loan, each adding new equity when the company is underperforming, can meaningfully erode a minority position. Co-investors and management equity holders sometimes push back on the breadth of the cure right during negotiation for that reason.